Effect of α-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention

Journal of the National Cancer Institute

Volumn 90, Issue 16, 1998, Pages 1212-1218

  Meyskens Jr , Frank L ^a   Gerner, Eugene W ^b   Emerson, Scott ^c   Pelot, Daniel ^a   Durbin, Theodore ^a   Doyle, Karen ^a   Lagerberg, Westley ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; POLYAMINE;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; DRUG EFFECT; DRUG EFFICACY; EPITHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL;

EID: 0042098091     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.16.1212     Document Type: Article

References (40)

1. Tabor H, Tabor CW, Cohn MS, Hafner EW. Streptomycin resistance (rpsL) produces an absolute requirement for polyamines for growth of an Esch-erichia coli strain unable to synthesize spermidine [delta(speA-speB) delta speC]. J Bacteriol 1981;147:702-4.
2. Balasundaram D, Tabor CW, Tabor H. Spermidine or spermine is essential for aerobic growth of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 1991;88:5872-6.
3. Mamont PS, Bohlen P. McCann PP, Bey P. Schuber F. Tardif C. Alphamethyl ornithine, a potent competitive inhibitor of ornithine decarboxylase, blocks proliferation of rat hepatoma cells in culture. Proc Natl Acad Sci U S A 1976;73:1626-30.
4. Weeks CE, Herrmann AL. Nelson FR, Slaga TJ. α-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci U S A 1982;79:6028-32.
5. Thompson HJ, Meeker LD, Herbst EJ, Ronan AM, Minocha R. Effect of concentration of D. L-2-difluoromethylornithine on murine mammary carcinogenesis. Cancer Res 1985;45:1170-3.
6. Nowels K, Homma Y, Seidenfeld J, Oyasu R. Prevention of inhibitory effects of alpha-difluoromethylornithine on rat urinary bladder carcinogenesis by exogenous putrescine, Cancer Biochem Biophys 1986;8:257-63.
7. Nigro ND, Bull AW, Boyd ME. Importance of the duration of inhibition on intestinal carcinogenesis by difluoromethylornithine in rats. Cancer Lett 1987;35:153-8.
8. Luk GD, Baylin SB. Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N Engl J Med 1984;311:80-3.
9. Hixson LJ, Garewal HS, McGee DL, Sloan D, Fennerty MB, Sampliner RE, et al. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev 1993;2:369-74.
10. Garewal HS, Sampliner R, Gerner E, Steinbronn K, Alberts D, Kendall D. Ornithine decarboxylase activity in Barrett's esophagus: a potential marker for dysplasia. Gastroenterology 1988;94:819-21.
11. Gray MR, Wallace HM, Goulding H, Hoffman J, Kenyon WE, Kingsnorth AN. Mucosal polyamine metabolism in the columnar lined oesophagus. Gut 1993;34:584-7.
12. Nishioka K, Melgarejo AB, Lyon RR, Mitchell MF. Polyamines as biomarkers of cervical intraepithelial neoplasia. J Cell Biochem Suppl 1995; 23:87-95.
13. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 1988;48:759-74.
14. McCann PP, Pegg AE. Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Ther 1992;54:195-215.
15. Levin VA, Chamberlain MC, Prados MD, Choucair AK, Berger MS, Silver P, et al. Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. Cancer Treat Rep 1987;71: 459-64.
16. Meyskens FL, Kingsley EM, Glattke T, Loescher L, Booth A. A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma, Invest New Drugs 1986;4:257-62.
17. Croghan MK, Aickin MG, Meyskens FL. Dose-related α-difluoromethylornithine ototoxicity. Am J Clin Oncol 1991;14:331-5.
18. Auvinen M. Cell transformation, invasion, and angiogenesis: a regulatory role for ornithine decarboxylase and polyamines? [editorial]. J Natl Cancer Inst 1997;89:533-7.
19. Kubota S, Kiyosawa H, Nomura Y, Yamada T, Seyama Y. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J Natl Cancer Inst 1997;89:567-71.
20. Wallon UM, Shassetz LR, Cress AE, Bowden GT, Gerner EW. Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line. Mol Carcinog 1994;11:138-44.
21. Creaven PJ, Pendyala L, Petrelli NJ. Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. Cancer Epidemiol Biomarkers Prev 1993;2: 243-7.
22. Greenwald P, Kelloff GJ, Boone CW, McDonald SS. Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Cancer Epidemiol Biomarkers Prev 1995;4:691-702.
23. Loprinzi CL, Messing EM, O' Fallon JR, Poon MA, Love RR, Quella SK. et al. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol Biomarkers Prev 1996;5:371-4.
24. Pasic TR, Heisey D, Love RR. α-Difluoromethylornithine ototoxicity. Chemoprevention clinical trial results. Arch Otolaryngol Head Neck Surg 1997;123:1281-6.
25. Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD. et al. Randomized phase 1 chemoprevention dose-seeking study of α-difluoromethylornithine. J Natl Cancer Inst 1993;85:732-6
26. Meyskens FL Jr, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J. et al. Dose de-escalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 1994;86:1122-30.
27. Hixson LJ. Emerson SS. Shassetz LR, Gerner EW. Sources of variability in measurements of ornithine decarboxylase activity and polyamine contents in colorectal mucosa. Cancer Epidemiol Biomarkers Prev 1994;3:317-23.
28. Boyle JO, Meyskens JL Jr. Garewal HS. Gerner EW. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 1992;1:131-5.
29. Seiler N. Knodgen B. High-performance liquid Chromatographic procedure for the simultaneous determination of the natural polyamines and their monoactyl derivatives. J Chromatogr 1980; 221:227-35.
30. Gerner EW, Garewal HG, Emerson SS. Sampliner RE. Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with α-difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 1994;3: 325-30.
31. Sarhan S, Knodgen B, Seiler N. The gastrointestinal tract as polyamine source for tumor growth. Anticancer Res 1989;9:215-23.
32. Meyskens FL Jr, Graham V, Chvapil M. Dorr RT, Alberts DS, Surwit EA. A phase I trial of β-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia, J Natl Cancer Inst 1983;71:921-5.
33. Graham V, Surwit ES, Weiner S, Meyskens FL Jr. Phase II trial of β-all-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap. West J Med 1986;145:192-5.
34. Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans retinoic acid: a randomized trial. J Natl Cancer Inst 1994;86:539-43.
35. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
36. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Prevention Study Group. N Engl J Med 1994;330:1029-35.
37. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
38. Mitchell MF, Hittelman WK, Lotan R, Nishioka K, Tortolero-Luna G, Richards-Kortum R, et al. Chemoprevention trials and surrogate end point biomarkers in the cervix, Cancer 1995;76(10 Suppl):1956-77.
39. Krishnan K, Brenner DE. Chemoprevention of colorectal cancer. Gastroenterol Clin North Am 1996;25:821-58.
40. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Sigman CC. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 1994;3:85-98.